Aduhelm fallout accumulates

Political fallout from FDA’s decision to grant accelerated approval to Aduhelm is accumulating, with two house committees launching investigations, requests for a Senate hearing, and now a call from Rep. Katie Porter (D-Calif.) for an investigation into pharma interactions with regulators.

Citing concerns about FDA’s accelerated approval of Aduhelm aducanumab from Biogen Inc. (NASDAQ:BIIB) and  Eisai Co. Ltd. (Tokyo:4523), Porter has requested that the HHS Inspector General “immediately investigate the role that pharmaceutical industry executives, consultants, and lobbyists have in the approval of products” by FDA...